Лого Српског лекарског друштва

Часопис Српског лекарског друштва

Српски архив за целокупно лекарство

Serbian Archives of Medicine

еКорпус – библиографски запис

Search for the presence of occult hepatitis C in patients with treatment-induced viral clearance using an ultrasensitive assay

Претрага за присуство окултног хепатитиса Ц код пацијенАта са терапиjском елиминацијом вируса применом ултрасензитивног теста

Pavlina Dzekova-Vidimliski; Igor G. Nikolov; Nadica Matevska-Geshkovska; Yana Boyanova; Nina Nikolova; Krasimir Antonov; Lyudmila Mateva; Aleksandar Dimovski; Lionel Rostaing; Aleksandar Šikole

Часопис
Serbian Archives of Medicine
Објављено
Srp Arh Celok Lek. 2016;144(7–8):418–423.
Врста рада
ORIGINAL ARTICLES

Abstract

Introduction Occult hepatitis C is defined by the presence of virus in the peripheral blood mononuclear cells (PBMCs) and/or liver cells, in the absence of serum viremia.

Objective To detect the persistence of occult hepatitis C in hemodialysis (HD) patients and patients without renal disease (non-renal) with treatment-induced clearance of hepatitis C virus (HCV) infection, using assays with a very low detection limit of viremia.

Methods A group of 13 HD patients and a group of 43 non-renal patients, with treatment-induced HCV infection clearance were investigated in the study. The HD patients were treated with pegylated interferon alpha (PEG-IFN-α) only, while the non-renal patients were treated with a combination therapy of PEG-IFN-α and ribavirin. Detection of a possible persistence of HCV RNA in the PBMCs and plasma samples was assessed by an ultrasensitive reverse transcription polymerase chain reaction (RT-PCR) assay (2 IU/ml).

Results HCV RNA was not detected in the PBMCs and plasma samples of HD patients and of non-renal patients, when assessed by the ultrasensitive RT-PCR assay.

Conclusion When a sensitive RT-PCR assay was applied, to determine if treatment induced clearance of HCV infection had been successful, occult hepatitis C could not be detected by an ultrasensitive assay, neither in HD nor in non-renal patients.

Keywords: hepatitis C virus; treatment, pegylated interferon α; ribavirin; hemodialysis; mononuclear leukocytes